Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

Overview

The purpose of this study is to investigate the effect synchronous use of nivolumab in addition to chemoradiotherapy in patients withnon-metastatic MIBC who are not candidates for radical cystectomy

Full Title of Study: “Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2022

Detailed Description

The initial hypothesis is that addition of nivolumab will increase 2-year locoregional control rate from 55% (control arm) to 75% (immunotherapy arm) There is a 24 month accrual period during which 78 patients will be randomized in a control group (standard chemo-radiotherapy) and the treatment group (chemo-radiotherapy + Nivolumab) The primary objective would be to compare locoregional control rate at 2-years between patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy. The secondary objectives are 1. To study the safety of the addition of nivolumab to chemoradiotherapy in patients with MIBC 2. To compare 2-year bladder cancer failure-free (BCFF) rates, defined as distant metastasis free survival (MFS) AND/OR locoregional failure (defined as in primary objective) 3. To compare median overall survival (OS) in patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy 4. Assess the effect of combined treatment on the quality of life Correlative studies of outcomes with PD-L1expression and with lymphocytic populations in the environment of the tumor

Interventions

  • Biological: Nivolumab
    • standard of care chemoradiotherapy + Nivolumab
  • Other: chemoradiotherapy
    • standard of care chemoradiotherapy

Arms, Groups and Cohorts

  • Other: Chemoradiotherapy
    • standard of care chemo-radiotherapy
  • Experimental: Combination
    • standard of care chemo-radiotherapy + Nivolumab

Clinical Trial Outcome Measures

Primary Measures

  • Locoregional control rate
    • Time Frame: 2 years
    • To compare locoregional control rate at 2-years between patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy

Secondary Measures

  • Incidence Rate of treatment-related adverse event (safety and tolerability)
    • Time Frame: 2 years
    • Incidence of adverse events as assessed by CTCAE. After radiotherapy completion, AEs will be assessed according to RTOG/EORTC Late Radiation Morbidity Scoring Schema
  • Bladder cancer failure-free (BCFF) rates
    • Time Frame: 2 years
    • To compare 2-year bladder cancer failure-free (BCFF) rates, defined as distant metastasis free survival (MFS) AND/OR locoregional failure (defined as in primary objective)
  • Median overall survival (OS)
    • Time Frame: 2 years
    • To compare median overall survival (OS) in patients with MIBC receiving or not receiving nivolumab in addition to chemoradiotherapy
  • Assessment of the effect of the combined treatment on the quality of life
    • Time Frame: 2 years
    • Quality of life score assessed by Quality of Life of Cancer Patients Questionnaire (EORTC QLQ-C30). Discomfort measured in a scale from 1 (not at all) to 4 (very much) Overall health and quality of life score measured in a scale from 1 (very poor) to 7 (excellent)

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically proven, muscle-invasive carcinoma of the bladder, cT2-T4aN0M0 – Urothelial, squamous or glandular histology according to WHO 2016 classification (Fig 1) – Undergone a vigorous TURB – Not candidates for radical cystectomy. – PS:0-1 – age >18 years old – Adequate bone marrow function – Adequate renal function Exclusion Criteria:

Key Exclusion Criteria

  • Histology other than transitional-cell, squamous or adenocarcinoma – Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, prostate cancer cervix or breast. – Previous systemic chemotherapy or prior biologic agents within 4 weeks, or intravesical Bacillus Calmette-Guerin (BCG) within 6 weeks of the first dose of study treatment. – Prior treatment with any PD-1 or PDL-1 inhibitor or anti CTLA4 agent – Previous pelvic radiation therapy. – Patients with inherited syndromes associated with hypersensitivity to ionizing radiation – Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation – Any history of inflammatory bowel disease and or history of abdominal fistula – Previous allergy to any of the study drugs

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hellenic GenitoUrinary Cancer Group
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Vasiliki Magoula, MSc, +302107777791, res2@eeoogek.gr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.